Please assess the completion status of the following clinical trial:

Trial Title: AUGMENTIN™ in Dental Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criterion:~  * Adult (≥18 years of age) males and females~ * Subjects with diagnosis of acute odontogenic infections of following types requiring antibiotic therapy~* Periapical abscess~* Aute periodontitis~* Pericoronitis • Provision of voluntary written informed consent~Exclusion Criteria:~* Subjects presenting with complications like osteomyelitis, dentocutaneous fistula, dentoalveolar fistula, draining sinus, facial-space swelling, necrotizing fasciitis OR subjects requiring hospitalization, aggressive intravenous antimicrobial therapy, requiring local application of antimicrobials for the treatment of odontogenic infection.~* Subjects presenting with odontogenic infections secondary to traumatic injury to the face.~* Subjects with valvular heart disease, prosthetic heart valves, congenital heart disease or any other conditions prone to infective endocarditis~* Subjects with a known clinically significant abnormality identified at screening on physical examination or known laboratory tests which, in the judgment of the Investigator, would preclude safe completion of the study~* Subject who has taken a systemic antibiotic within 2 weeks before study drug administration or a long-acting injectable antibiotic (e.g., penicillin G benzathine) within 4 weeks before study drug administration~* Immunocompromised subjects or subjects on immunosuppressants or systemic corticosteroids~* Subjects with chronic gingivitis or chronic periodontitis~* Subjects with uncontrolled diabetes mellitus or HIV infection~* History of hypersensitivity or allergic reactions to any beta-lactam such as penicillin, cephalosporin, moxicillin/clavulanic acid or clindamycin~* Concomitant infection, that requires additional antimicrobial therapy during the study period~* Subjects with clinically significant liver disease as defined by alanine aminotransferase (ALT) or aspartate minotransferase (AST) levels \>2.5 times the upper limit of normal (ULN) or a diagnosis of chronic active hepatitis including that of viral etiology, or on antiviral or immunosuppressive therapy.~* Subjects with renal impairment with serum creatinine \> 1.7 mg/dl in men and \>1.5mg/dl in women.~* Subjects with infectious mononucleosis~* Subjects with history of documented Clostridium difficile-associated diarrhoea or existing diarrhoea~* Concomitant treatment with oral anticoagulants, methotrexate or probenicid~* Female subjects of childbearing potential in whom pregnancy cannot be excluded by a negative pregnancy test and who are not using reliable method of contraception~* Subjects with lactose intolerance or Lapp lactase deficiency or glucose-galactose malabsorption~* Pregnant or lactating female subjects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Amoxicillin/clavulanate (Type: ACTIVE_COMPARATOR): Amoxicillin/ clavulanate 1 g bd for for at least 5 days upto seven days depending on treament response
- Clindamycin (Type: ACTIVE_COMPARATOR): Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon treatment response

Based on this trial design, predict the completion outcome and termination type (if applicable).